Professor Andrew Roberts – Blood Cells & Blood Cancer division

19/06/2024 1:00 pm - 19/06/2024 2:00 pm
Davis Auditorium

WEHI Wednesday Seminar hosted by Professor Warren Alexander

Professor Andrew Roberts

Laboratory Head & Theme Leader – Blood Cells & Blood Cancer division – Cancer Research & Treatments Theme, WEHI


Venetoclax for blood cancer: exploring beyond the headline approvals


Davis Auditorium

Join via SLIDO enter code #WEHIWednesday

Including Q&A session




Venetoclax is the first approved drug in a new class of anti-cancer drugs, BH3 mimetics, made possible by the discovery of the function of BCL2 and breakthrough research in cell death at WEHI. By specifically inhibiting BCL2, venetoclax directly triggers apoptosis without first damaging DNA or necessarily requiring TP53 function. First approved for selected patients with chronic lymphocytic leukaemia (CLL) in 2016, it is now a standard-of-care treatment for both CLL and acute myeloid leukaemia globally. However, there is still much to learn about what the drug is, and is not, capable of for treatment of these and other blood cancers. Andrew Roberts is an academic pioneer in venetoclax and BH3 mimetic research, both preclinical and clinical. He will present several vignettes illustrating what we know about resistance to BCL2 inhibition in patients and how we might go about circumventing this now with existing tools in investigator-initiated trials, and in the future after further discovery research.




All welcome!

Support us

Together we can create a brighter future

Your support will help WEHI’s researchers make discoveries and find treatments to ensure healthier, longer lives for you and your loved ones.

Sign up to our quarterly newsletter Illuminate

Find out about recent discoveries, community supporters and more.

Illuminate Winter 2024
View the current issue